COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,903 Articles (22,568 medRxiv, 8,335 bioRxiv)

Most recent first Previous |  Page 1183: Articles 11821-11830  | Next

Acquired peripheral nerve injuries associated with severe COVID-19
Franz, C. K., Murthy, N. K., Malik, G. R., Kwak, J. W., D'Andrea, D., Wolfe, A. R., Farr, E., Stearns, M. A., Deshmukh, S., Tavee, J. O., Sun, F., Swong, K. N., Rydberg, L., Cotton, R. J., Wolfe, L. F., Walter, J. M., Coleman, J. M., Rogers, J. A.
10.1101/2021.09.24.21263996 — Posted: 2021-09-27
The kinetic of SARS-CoV-2 antibody (Ab) decline determines the threshold for Ab persistence up to one year
Garner-Spitzer, E., Wagner, A., Kundi, M., Stockinger, H., Repic, A., Schoetta, A.-M., Gudipati, V., Huppa, J. B., Kunert, R., Mayrhofer, P., Kreil, T. R., Farcet, M. R., Hoeltl, E., Wiedermann, U.
10.1101/2021.09.20.21263172 — Posted: 2021-09-27
Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint
Chen, X., Wang, W., Chen, X., Wu, Q., Sun, R., Ge, S., Zheng, N., Lu, W., Yang, J., Rodewald, L., Yu, H.
10.1101/2021.09.23.21263715 — Posted: 2021-09-27
Diagnostic Yield of Screening for SARS-CoV-2 among Patients Admitted for Alternate Diagnoses
Davis, P., Rosychuk, R. J., Hau, J. P., Cheng, I., McRae, A. D., Daoust, R., Lang, E., Turner, J., Khangura, J., Fok, P. T., Stachura, M., Brar, B., Hohl, C. M.
10.1101/2021.09.23.21264036 — Posted: 2021-09-27
The Report on China-Spain Joint Clinical Testing for Rapid COVID-19 Risk Screening by Eye-region Manifestations
Fu, Y., Li, F., Fustel, P. b., Zhao, L., Jia, L., Zheng, H., Sun, Q., Rong, S., Tang, H., Xue, X., Yang, L., Li, H., Xie, J., Wang, W., Li, Y., Wang, W., Pei, Y., Wang, J., Wu, X., Zheng, Y., Tian, H., Gu, M.
10.1101/2021.09.24.21263766 — Posted: 2021-09-27
The International Sexual Health And Reproductive Health Survey (I-SHARE-1): A Cross-Sectional Multi-Country Analysis of Adults from 30 Countries Prior to and During the Initial COVID-19 Wave
Erausquin, J. T., Tan, R. K. J., Uhlich, M., Francis, J. M., Kumar, N., Campbell, L., Zhang, W.-H., Hlatshwako, T. G., Kosana, P., Shah, S., Brenner, E. M., Remmerie, L., Mussa, A., Klapilova, K., Mark, K., Perotta, G., Gabster, A., Wouters, E., Burns, S., Hendriks, J., Hensel, D. J., Shamu, S., Strizzi, J. M., Esho, T., Morroni, C., Eleuteri, S., Sahril, N., Low, W. Y., Plasilova, L., Lazdane, G., Olumide, A., Michielsen, K., Moreau, C., Tucker, J. D., I-SHARE research consortium
10.1101/2021.09.18.21263630 — Posted: 2021-09-27
SARS-CoV-2 spike-specific memory B cells express markers of durable immunity after non-severe COVID-19 but not after severe disease
Reyes, R., Clarke, K., Gonzales, S. J., Cantwell, A. M., Garza, R., Catano, G., Tragus, R. E., Patterson, T. F., Bol, S., Bunnik, E. M.
10.1101/2021.09.24.461732 — Posted: 2021-09-27
Spike independent replication of human coronavirus in bat cells
Linster, M., Mah, M. G., Low, D. H., Yan, Z., Jayakumar, J., Samsudin, F., Wong, F. Y., Bond, P. J., Mendenhall, I. H., Su, Y. C., Smith, G. J.
10.1101/2021.09.18.460924 — Posted: 2021-09-27
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patients
Pitzalis, M., Idda, M. L., Lodde, V., Loizedda, A., Lobina, M., Zoledzwieska, M., Virdis, F., Delogu, G., Pirinu, F., Marini, M. G., Mingoia, M., Frau, J., Lorefice, L., Fronza, M., Carmagini, D., Carta, E., Orru, V., Uzzau, S., Solla, P., Loi, F., Devoto, M., Steri, M., Fiorillo, E., Floris, M., Zarbo, I. R., Cocco, E., Cucca, F.
10.1101/2021.09.26.21264067 — Posted: 2021-09-27
Intravenous Immunoglobulin (IVIG) in Treating Non-ventilated COVID-19 Patients with Moderate to Severe Hypoxia is Pharmacoeconomically Favorable When Appropriately Targeted
Poremba, M., Dehner, M., Perreiter, A., Semma, A., Mills, K., Sakoulas, G.
10.1101/2021.09.26.21264152 — Posted: 2021-09-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).